Guerbet SA (EPA:GBT)

France flag France · Delayed Price · Currency is EUR
13.12
+0.26 (2.02%)
Sep 26, 2025, 5:35 PM CET
2.02%
Market Cap165.36M
Revenue (ttm)820.92M
Net Income (ttm)7.74M
Shares Out12.60M
EPS (ttm)0.62
PE Ratio21.27
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume206,956
Average Volume53,163
Open13.00
Previous Close12.86
Day's Range12.96 - 13.40
52-Week Range12.72 - 39.35
Beta0.79
RSI20.82
Earnings DateSep 24, 2025

About Guerbet

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine; Elucirem, a macrocyclic gadolinium-based contrast agent; and Artirem, a gadoteric acid that acts a... [Read more]

Sector Healthcare
Founded 1926
Employees 2,905
Stock Exchange Euronext Paris
Ticker Symbol GBT
Full Company Profile

Financial Performance

In 2024, Guerbet's revenue was 851.12 million, an increase of 6.97% compared to the previous year's 795.65 million. Earnings were 16.08 million, a decrease of -32.61%.

Financial Statements

News

There is no news available yet.